Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0FGLFW
ADC Name
ATG-022
Synonyms
ATG 022; ATG022; ATG-022 ADC
   Click to Show/Hide
Organization
Antengene Corporation Co., Ltd.
Drug Status
Phase 1
Indication
In total 2 Indication(s)
Gastric cancer [ICD11:2B72]
Phase 1
Solid tumors [ICD11:2A00-2A0Z|2B50-2F9Z]
Phase 1
Antibody Name
Undisclosed
Antigen Name
Claudin-18.2 (CLDN18.2)
  Antigen Info 
Payload Name
Undisclosed
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05718895
Phase 1
An open, multi-center, phase 1 clinical study of ATG 022 in patients with advanced/metastatic solid tumors.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05718895  Clinical Status Phase 1
Clinical Description An open, multi-center, phase 1 clinical study of ATG 022 in patients with advanced/metastatic solid tumors.
References
Ref 1 An Open, Multi-center, Phase I Clinical Study of ATG 022 in Patients With Advanced/Metastatic Solid Tumors, NCT05718895

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.